Hyperfine, Inc. (HYPR) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. Hyperfine, Inc. is an innovative health technology company developing the Swoop® Portable MR Imaging® System, an AI-powered, ultra-low-field (ULF) magnetic resonance brain imaging device. The company operates as a single reportable segment focused on the production, supply, service, and commercialization of the Swoop® system. As of June 30, 2026, the company had $43.5 million in cash and cash equivalents.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | YTD 2026 (6 Months) | Q2 2025 (3 Months) | YTD 2025 (6 Months) |
|---|---|---|---|---|
| Total Revenue | $3.9 million | $7.8 million | $2.7 million | $4.8 million |
| Gross Profit | $2.0 million | $4.0 million | $1.3 million | $2.2 million |
| Gross Margin | 50.7% | 50.7% | 49.3% | 45.7% |
| Net Loss | $(9.3) million | $(17.9) million | $(9.2) million | $(18.6) million |
| Operating Cash Flow | N/A | $(16.3) million | N/A | $(17.2) million |
| Long-Term Debt (Net) | $13.2 million | $13.2 million | $0 | $0 |
| Cash & Equivalents | $43.5 million | $43.5 million | $35.1 million | $35.1 million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 44.8% in Q2 2026 and 61.5% YTD compared to the prior year periods. This was driven by a 49.0% increase in device sales (12 units sold in Q2 2026 vs. 8 in Q2 2025) and a 29.2% increase in service revenue.
- Expense Management: Research and Development (R&D) expenses decreased by 14.9% in Q2 2026 and 19.5% YTD, primarily due to lower headcount and increased grant fulfillment credits. General and Administrative (G&A) expenses remained relatively flat.
- Debt Financing: In March 2026, the company entered into a Loan Agreement with Horizon Technology Finance Corporation, borrowing $15.0 million of a $40.0 million facility. This resulted in new interest expense of $0.5 million for Q2 2026, compared to zero in the prior year.
- Equity Financing: The company raised approximately $10.6 million in net proceeds during Q2 2026 through its "at-the-market" (ATM) sales agreement.
- Warrant Liability: The company recorded a non-cash loss of $0.6 million in Q2 2026 related to the change in fair value of warrant liabilities, compared to a gain of $0.05 million in Q2 2025.
Guidance, Outlook, and Risks
- Product Milestones: In March 2026, the company received CE Mark and UKCA Mark approval for its next-generation Swoop® scanner and Optive AI™ software, enabling commercialization in Europe. In December 2025, FDA clearance was received for the eleventh-generation software featuring multi-direction DWI for improved stroke detection.
- Liquidity Outlook: Management believes existing cash resources, combined with anticipated revenue and the new debt facility, are sufficient to fund operations for at least the next 12 months. However, the company continues to incur net losses and expects to require additional financing in the future.
- Risks: Key risks include the company's history of losses and ability to continue as a going concern, reliance on single-source manufacturers, regulatory approval uncertainties, and the impact of geopolitical conflicts and inflation on supply chains and costs.
- Grant Funding: The company continues to receive significant grant funding from the Bill & Melinda Gates Foundation (BMGF), with a new $3.7 million award in November 2025 extending through March 2028 to support neonatal brain imaging innovation.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the current cash position ($43.5M) against the operating cash burn of ~$16.3M for the six-month period.
- Debt Covenants: Review the specific financial covenants in the March 2026 Loan Agreement to ensure compliance and understand restrictions on future capital raising.
- Revenue Concentration: Note that for the three months ended June 30, 2026, three customers each represented over 10% of total net revenue.
- Warrant Liability Volatility: Monitor the fair value of warrant liabilities, which fluctuated significantly and impacted net loss in the current period.
- Regulatory Status: Confirm the commercial rollout progress of the next-generation Swoop® system in the U.S. and European markets following recent approvals.